Format

Send to

Choose Destination
Life Sci. 2013 Feb 7;92(2):114-8. doi: 10.1016/j.lfs.2012.11.004. Epub 2012 Nov 15.

Nonalcoholic fatty liver disease: current and potential therapies.

Author information

1
Department of Pharmacology, Faculty of Medicine, Minia University, Egypt. maim69@yahoo.com

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury worldwide. It covers a wide spectrum of hepatic disorders ranging from simple steatosis, through steatohepatitis (steatosis with inflammation), to cirrhosis. The molecular and cellular mechanisms underlying hepatic injury in NAFLD are not clear. Several evidences suggest that multiple mechanisms including insulin resistance, oxidative stress, inflammation, and genetic factors interact to initiate the development of NAFLD. Despite that there is currently no approved drug therapy for NAFLD, many approaches appear to be beneficial. Insulin sensitizers, antioxidants and antiinflammatory agents showed promising effects. This review highlights the current as well as the potential therapies of NAFLD.

PMID:
23159641
DOI:
10.1016/j.lfs.2012.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center